New tip sheet available for the Behavioral Health HEDIS measure: Follow-Up Care for Children Prescribed ADHD Medication (ADD)

Nov. 2022Important Notices
The ADD HEDIS® measure outlines the importance for members 6 to 12 years old who are newly prescribed a medication for ADHD to receive, at minimum, three appointments—an initial appointment with the prescriber and subsequent appointments with the treatment team, including behavioral health treatment providers—within 10 months of starting the new medication. The tip sheet defines the HEDIS measure and offers providers tips to ensure continuity of care for their patients who are prescribed medications for ADHD for the first time. Learn more about the ADD HEDIS measure.

HEDIS®
The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA.

Recent Announcements

Voluntary nationwide recall: Cetirizine (Unique – July)

Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) is recalling four lots (GY825029, GY825030, GY825031, GY825032) of Cetirizine Hydrochloride Tablets USP 5 mg. Cetirizine is used for the relief of allergy symptoms, including itchy, red, watery eyes and itchy skin.
Jul. 2026Pharmacy Updates

August 2026 UPMC for You and UPMC Community HealthChoices Formulary Updates

Effective Aug. 15, 2026, UPMC for You and UPMC Community HealthChoices are updating their formularies.
Jul. 2026Pharmacy Updates

Give feedback on your experience with UPMC Health Plan

 You may be invited to participate in a 2026 Press Ganey provider satisfaction survey, which will begin next month. This survey will be given to a random sampling of in-network primary care providers.
Jul. 2026Important Notices